Developer docs
API playgroundTry for free, no card

Search company profiles

Syschem

Full company profile

uuid003kruk

Namestring
Syschem
Legal namestring
Syschem (India) Limited
Websiteurl
syschem.in
Company typeenum
Public
Founded yearstring
-
Descriptiontext

Syschem (India) Limited is a BSE-listed pharmaceutical manufacturer (Scrip Code 531173, ISIN INE121D01036) headquartered in Chandigarh with manufacturing operations in Panchkula, Haryana. The company produces Active Pharmaceutical Ingredients (APIs) and intermediates — including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium — alongside specialty chemicals and a broad portfolio of finished generic formulations spanning tablets, softgel capsules, injections, syrups/suspensions, and herbal/personal care products across antibiotics, anti-ulcerants, analgesics, neuroprotective agents, hormonal therapies, and nutritional supplements. Manufacturing is GMP-certified (2023) with ISO quality management and supported by an in-house R&D centre equipped with pilot-scale production capabilities for developing non-infringing Drug Master File (DMF) processes.

The business operates on a B2B sales-led model with two principal revenue streams: API/intermediate/contract manufacturing sales to domestic and international pharmaceutical companies, and branded generic formulation sales to domestic healthcare providers. Distribution is conducted through a direct sales force with dedicated international business development personnel, including a Senior Manager-International Business (API) and a GM Business Development focused on import/export. The company's go-to-market relies on direct outreach, a corporate website with product catalogs, and an extensive investor relations portal reflecting its public-company status. Pricing is quote-based with no public disclosure, and specific revenue figures, customer concentration, and headcount data are not disclosed.

Syschem has raised equity capital through two preferential issues in 2022 and 2024 to fund expansion, and its regulatory posture — including GMP certification, an EC grant, and DMF filings — indicates pursuit of regulated international markets for API exports. Governance is via a standard public-company board with promoter-led management control (Managing Director Ranjan Jain since 2011, Whole-Time Director Suninder Veer Singh since 2016), independent directors, and a Company Secretary. Notable risks visible in public disclosures include a show cause notice, an order for recovery of money, and a Regulation 30 QP pharma case closure, which warrant diligence alongside the absence of disclosed revenue and customer concentration metrics.

Short descriptiontext

Syschem (India) Limited is a BSE-listed pharmaceutical manufacturer producing APIs, intermediates, specialty chemicals, and over 100 generic formulations (tablets, capsules, injections, syrups) for domestic and international B2B pharmaceutical customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersChandigarh, India
HQ citystring
Chandigarh
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, bulk drug manufacturing, pharmaceutical intermediates, generic formulations, contract manufacturing
Industry2 codes
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing (APIs and Generic Formulations)
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1API/Intermediates Manufacturing
TypeOne Time License
Description

Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium to pharmaceutical companies.

syschem.in
2Generic Formulations
TypeOne Time License
Description

Production and sale of generic pharmaceutical formulations including Tablets, Softgel/Capsules, Injections, Syrups & Suspensions, and Herbal & Personal Care products.

syschem.in
3Contract Manufacturing
TypeProfessional Services
Description

Custom manufacturing services for pharmaceutical companies requiring specialized production capabilities.

syschem.in
4Specialty Chemicals
TypeOne Time License
Description

Manufacturing of specialty chemicals for pharmaceutical and related industries.

syschem.in
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1B2B pharmaceutical products and contract manufacturing services
ModelOther
Notes

Pricing not publicly disclosed. Transactions appear to be quote-based for APIs, intermediates, and formulation products.

syschem.in
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1Cefo-Zone
Description

Antibiotic injection product

syschem.in
+11 more records
Core offering1 text field

Syschem (India) Limited manufactures and sells Active Pharmaceutical Ingredients (APIs) including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. The company also produces specialty chemicals, pharmaceutical intermediates, and a broad range of generic finished dosage forms (tablets, capsules, softgels, injections, syrups, and herbal/personal care products) for domestic and international pharmaceutical buyers, and offers contract manufacturing services.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Syschem (India) Limited is a pharmaceutical company engaged in the manufacture of Bulk Drugs/Intermediates/Specialty Chemicals and contract manufacturing. The company's product portfolio consists of: (1) API/Intermediates including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium used as foundational ingredients for formulations; (2) Generic finished dosage forms including Tablets (antibiotics, analgesics, nutritional supplements), Softgels/Capsules (anti-ulcerants, neuroprotective agents, antibiotics, hormonal products), Injections (antibiotics, steroids, nutritional supplements, antimalarials), Syrups/Suspensions (cough syrups, digestive aids, nutritional supplements), and Herbal/Personal Care products. The products serve multiple therapeutic categories including antibiotics, anti-ulcerants, neuroprotective agents, hormonal therapies, nutritional supplements, respiratory treatments, and hepatoprotective formulations.

Product and service12 records
1Amoxycillin Tri Hydrate API
CategoryAPI / Intermediates
Description

Active Pharmaceutical Ingredient used as a beta-lactam antibiotic in the manufacture of various formulations, sold to pharmaceutical companies.

2Ampicillin Tri Hydrate API
CategoryAPI / Intermediates
Description

Active Pharmaceutical Ingredient with antibiotic properties used as a foundational ingredient in pharmaceutical manufacturing.

3Cloxacillin Sodium API
CategoryAPI / Intermediates
Description

Beta-lactam antibiotic API used in the production of semi-synthetic penicillins for pharmaceutical manufacturers.

4Dicloxacillin Sodium API
CategoryAPI / Intermediates
Description

Penicillinase-resistant antibiotic API for manufacturing anti-infective medications.

5Flucloxacillin Sodium API
CategoryAPI / Intermediates
Description

Beta-lactamase resistant antibiotic API used in pharmaceutical formulations.

6Generic Tablets (Antibiotics, Analgesics, Nutritional)
CategoryGeneric Formulations - Tablets
Description

Broad portfolio of generic finished tablet dosage forms spanning antibiotics (SYSCLAV-625, AZICHEM 500, SYSFLOX-500), analgesics (SYSFEN-P, SYSFEN-SP), nutritional supplements (SYSFER-XT, CHEM-VIT), anti-ulcerants, anti-allergics (MONTE-LC), corticosteroids (DIZCORT 6), and anti-cold (SYSCOLD) preparations.

7Generic Softgel/Capsule Products
CategoryGeneric Formulations - Softgel/Capsule
Description

Range of softgel capsules and capsules including anti-ulcerants (PANTOSYS-DSR, RABEZOLE-DSR, OMESYS, OMESYS-DSR), neuroprotective agents (SYSBAL PLUS, SYSBAL PG), antibiotics (SYSMOX 250/500/DC), anti-fungals (ITROSYS 100/200), hormonal supplements (PREGACARE 100/200), and nutraceutical softgels (GLUTASYS, SHAKTI 40, SYSCAL-CT, OMEGASYS-G3, SYSCAL-60K, VEE SAFE).

8Generic Injection Products
CategoryGeneric Formulations - Injections
Description

Sterile injectable pharmaceutical products including antibiotic injections (SEFXONE, CEFO-ZONE-S, SYSDIME, AZTREOSYS, SYSPIME, MEROSYS, VANCOSYS, SYPTAZ, IMILIFE-500, DORISYS, CHEMCIN), anti-analgesic injections (TRAMASYS, DICLOSYS-IV, PIROSYS-IV), hormonal injections (PREGASYS, PREGACARE INJ, ND 50, ND 25), corticosteroids (HYDROSYS), anti-ulcerant injections (PANTOSYS-IV, OMESYS-40 Inj, ESOMESYS-40 Inj), antimalarials (ARTESYS, RT-THER), neuroprotective and nutritional injections (CITISYS, MED-VIT INJ, SYSBAL-IV/FORTE), and supportive care injections (SYSRTON-INJ, TIGESYS-IV, CLINDASYS, SYSROSE-IV, COLISYS, SYSCLAV INJ).

9Generic Syrups and Suspensions
CategoryGeneric Formulations - Syrups/Suspensions
Description

Liquid oral pharmaceutical preparations including cough syrups (KUFKIL-LT, KUFKIL-DX), digestive syrups (SYSZYME), appetizer syrups (C-HEPRO T), multivitamin and mineral syrups (MED-VIT, CALCIWIN, LYCOSYS, SYSFER-XT suspension), and protein tonics (PRORICH-L).

10Herbal and Personal Care Products
CategoryHerbal & Personal Care
Description

Herbal and personal care pharmaceutical products including uterine tonic (GYNESYS), hepatoprotective liver tonic (LIVOSYS-DS), and protein powder with DHA and minerals (PROWIN DHA).

11Contract Manufacturing Services
CategoryContract Manufacturing Services
Description

Custom pharmaceutical manufacturing services for pharmaceutical companies requiring specialized production of bulk drugs and formulations at the company's GMP-certified facility in Panchkula.

12Specialty Chemicals
CategorySpecialty Chemicals
Description

Specialty chemicals manufactured for pharmaceutical and related industries, including intermediates used in the production of bulk drugs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers5 records
TypeBroad incumbent
Description

Indian pharma with significant cephalosporin and penicillin API manufacturing and US/EU DMF portfolio, closely mirroring Syschem's API focus and regulated-market strategy.

TypeBroad incumbent
Description

Dominant Indian branded-generics company with extensive anti-infective, gastro, and nutraceutical portfolio directly overlapping Syschem's formulation range, though at vastly larger scale and brand investment.

TypeBroad incumbent
Description

Indian branded-generics and API manufacturer with strong domestic acute-care portfolio (anti-infectives, gastro) overlapping Syschem's therapeutic mix, but with a much larger field force and export footprint.

TypeBroad incumbent
Description

Major Indian pharma with broad API and formulation capabilities, including antibiotics and injectables, plus strong international/export presence — comparable product mix and regulatory ambitions.

TypeBroad incumbent
Description

Large Indian API and finished-formulation manufacturer with significant US/EU DMF presence and penicillin/cephalosporin API capabilities — directly comparable product overlap, but at materially larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syschem

Pharmaceutical Manufacturing (APIs and Generic Formulations)syschem.in

Syschem (India) Limited is a BSE-listed pharmaceutical manufacturer producing APIs, intermediates, specialty chemicals, and over 100 generic formulations (tablets, capsules, injections, syrups) for domestic and international B2B pharmaceutical customers.

What Syschem does

Syschem (India) Limited is a BSE-listed pharmaceutical manufacturer (Scrip Code 531173, ISIN INE121D01036) headquartered in Chandigarh with manufacturing operations in Panchkula, Haryana. The company produces Active Pharmaceutical Ingredients (APIs) and intermediates — including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium — alongside specialty chemicals and a broad portfolio of finished generic formulations spanning tablets, softgel capsules, injections, syrups/suspensions, and herbal/personal care products across antibiotics, anti-ulcerants, analgesics, neuroprotective agents, hormonal therapies, and nutritional supplements. Manufacturing is GMP-certified (2023) with ISO quality management and supported by an in-house R&D centre equipped with pilot-scale production capabilities for developing non-infringing Drug Master File (DMF) processes.

The business operates on a B2B sales-led model with two principal revenue streams: API/intermediate/contract manufacturing sales to domestic and international pharmaceutical companies, and branded generic formulation sales to domestic healthcare providers. Distribution is conducted through a direct sales force with dedicated international business development personnel, including a Senior Manager-International Business (API) and a GM Business Development focused on import/export. The company's go-to-market relies on direct outreach, a corporate website with product catalogs, and an extensive investor relations portal reflecting its public-company status. Pricing is quote-based with no public disclosure, and specific revenue figures, customer concentration, and headcount data are not disclosed.

Syschem has raised equity capital through two preferential issues in 2022 and 2024 to fund expansion, and its regulatory posture — including GMP certification, an EC grant, and DMF filings — indicates pursuit of regulated international markets for API exports. Governance is via a standard public-company board with promoter-led management control (Managing Director Ranjan Jain since 2011, Whole-Time Director Suninder Veer Singh since 2016), independent directors, and a Company Secretary. Notable risks visible in public disclosures include a show cause notice, an order for recovery of money, and a Regulation 30 QP pharma case closure, which warrant diligence alongside the absence of disclosed revenue and customer concentration metrics.

Syschem firmographics

Firmographics
Name
Syschem
Legal name
Syschem (India) Limited
Website
https://syschem.in
Company type
Public
Operating status
Operating
Headcount range
51–100 employees
Short description
Syschem (India) Limited is a BSE-listed pharmaceutical manufacturer producing APIs, intermediates, specialty chemicals, and over 100 generic formulations (tablets, capsules, injections, syrups) for domestic and international B2B pharmaceutical customers.
Ownership category
akta.pro rank

Syschem industry classification

Industry
Product category
Pharmaceutical Manufacturing (APIs and Generic Formulations)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Active pharmaceutical ingredients
  • Bulk drug manufacturing
  • Pharmaceutical intermediates
  • Generic formulations
  • Contract manufacturing

Where Syschem is headquartered

Location

Headquarters

HQ city
Chandigarh
HQ country
India
HQ region
Asia

Offices2 records

Markets served

Syschem business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. API/Intermediates Manufacturing: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium to pharmaceutical companies.
  2. Generic Formulations: Production and sale of generic pharmaceutical formulations including Tablets, Softgel/Capsules, Injections, Syrups & Suspensions, and Herbal & Personal Care products.
  3. Contract Manufacturing: Custom manufacturing services for pharmaceutical companies requiring specialized production capabilities.
  4. Specialty Chemicals: Manufacturing of specialty chemicals for pharmaceutical and related industries.

Pricing tiers

ModelBillingPrice
Other—B2B pharmaceutical products and contract manufacturing services

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Syschem product offering

Product offering

Core offering

Syschem (India) Limited manufactures and sells Active Pharmaceutical Ingredients (APIs) including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. The company also produces specialty chemicals, pharmaceutical intermediates, and a broad range of generic finished dosage forms (tablets, capsules, softgels, injections, syrups, and herbal/personal care products) for domestic and international pharmaceutical buyers, and offers contract manufacturing services.

Product overview

Syschem (India) Limited is a pharmaceutical company engaged in the manufacture of Bulk Drugs/Intermediates/Specialty Chemicals and contract manufacturing. The company's product portfolio consists of: (1) API/Intermediates including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium used as foundational ingredients for formulations; (2) Generic finished dosage forms including Tablets (antibiotics, analgesics, nutritional supplements), Softgels/Capsules (anti-ulcerants, neuroprotective agents, antibiotics, hormonal products), Injections (antibiotics, steroids, nutritional supplements, antimalarials), Syrups/Suspensions (cough syrups, digestive aids, nutritional supplements), and Herbal/Personal Care products. The products serve multiple therapeutic categories including antibiotics, anti-ulcerants, neuroprotective agents, hormonal therapies, nutritional supplements, respiratory treatments, and hepatoprotective formulations.

Differentiator

Problem solved

Functional benefit

Brands

  • Cefo-Zone: Antibiotic injection product
  • Chemcin 500
  • Pantosys
  • Sefxone
  • Med-Vit
  • Lyc-Sys
  • Syszyme
  • Sysclav
  • SYSMOX
  • OMESYS
  • VANCOSYS
  • MEROSYS

Products and services

  • Amoxycillin Tri Hydrate API Active Pharmaceutical Ingredient used as a beta-lactam antibiotic in the manufacture of various formulations, sold to pharmaceutical companies.
  • Ampicillin Tri Hydrate API Active Pharmaceutical Ingredient with antibiotic properties used as a foundational ingredient in pharmaceutical manufacturing.
  • Cloxacillin Sodium API Beta-lactam antibiotic API used in the production of semi-synthetic penicillins for pharmaceutical manufacturers.
  • Dicloxacillin Sodium API Penicillinase-resistant antibiotic API for manufacturing anti-infective medications.
  • Flucloxacillin Sodium API Beta-lactamase resistant antibiotic API used in pharmaceutical formulations.
  • Generic Tablets (Antibiotics, Analgesics, Nutritional) Broad portfolio of generic finished tablet dosage forms spanning antibiotics (SYSCLAV-625, AZICHEM 500, SYSFLOX-500), analgesics (SYSFEN-P, SYSFEN-SP), nutritional supplements (SYSFER-XT, CHEM-VIT), anti-ulcerants, anti-allergics (MONTE-LC), corticosteroids (DIZCORT 6), and anti-cold (SYSCOLD) preparations.
  • Generic Softgel/Capsule Products Range of softgel capsules and capsules including anti-ulcerants (PANTOSYS-DSR, RABEZOLE-DSR, OMESYS, OMESYS-DSR), neuroprotective agents (SYSBAL PLUS, SYSBAL PG), antibiotics (SYSMOX 250/500/DC), anti-fungals (ITROSYS 100/200), hormonal supplements (PREGACARE 100/200), and nutraceutical softgels (GLUTASYS, SHAKTI 40, SYSCAL-CT, OMEGASYS-G3, SYSCAL-60K, VEE SAFE).
  • Generic Injection Products Sterile injectable pharmaceutical products including antibiotic injections (SEFXONE, CEFO-ZONE-S, SYSDIME, AZTREOSYS, SYSPIME, MEROSYS, VANCOSYS, SYPTAZ, IMILIFE-500, DORISYS, CHEMCIN), anti-analgesic injections (TRAMASYS, DICLOSYS-IV, PIROSYS-IV), hormonal injections (PREGASYS, PREGACARE INJ, ND 50, ND 25), corticosteroids (HYDROSYS), anti-ulcerant injections (PANTOSYS-IV, OMESYS-40 Inj, ESOMESYS-40 Inj), antimalarials (ARTESYS, RT-THER), neuroprotective and nutritional injections (CITISYS, MED-VIT INJ, SYSBAL-IV/FORTE), and supportive care injections (SYSRTON-INJ, TIGESYS-IV, CLINDASYS, SYSROSE-IV, COLISYS, SYSCLAV INJ).
  • Generic Syrups and Suspensions Liquid oral pharmaceutical preparations including cough syrups (KUFKIL-LT, KUFKIL-DX), digestive syrups (SYSZYME), appetizer syrups (C-HEPRO T), multivitamin and mineral syrups (MED-VIT, CALCIWIN, LYCOSYS, SYSFER-XT suspension), and protein tonics (PRORICH-L).
  • Herbal and Personal Care Products Herbal and personal care pharmaceutical products including uterine tonic (GYNESYS), hepatoprotective liver tonic (LIVOSYS-DS), and protein powder with DHA and minerals (PROWIN DHA).
  • Contract Manufacturing Services Custom pharmaceutical manufacturing services for pharmaceutical companies requiring specialized production of bulk drugs and formulations at the company's GMP-certified facility in Panchkula.
  • Specialty Chemicals Specialty chemicals manufactured for pharmaceutical and related industries, including intermediates used in the production of bulk drugs.

Companies that use Syschem

Customer profile

Segments2 records

Ideal customer profiles2 records

Syschem technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Syschem partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Syschem competitors and assessment

Company assessment

Broad incumbents

  • Lupin: Indian pharma with significant cephalosporin and penicillin API manufacturing and US/EU DMF portfolio, closely mirroring Syschem's API focus and regulated-market strategy.
  • Mankind Pharma: Dominant Indian branded-generics company with extensive anti-infective, gastro, and nutraceutical portfolio directly overlapping Syschem's formulation range, though at vastly larger scale and brand investment.
  • Alkem Laboratories: Indian branded-generics and API manufacturer with strong domestic acute-care portfolio (anti-infectives, gastro) overlapping Syschem's therapeutic mix, but with a much larger field force and export footprint.
  • Cipla: Major Indian pharma with broad API and formulation capabilities, including antibiotics and injectables, plus strong international/export presence — comparable product mix and regulatory ambitions.
  • Aurobindo Pharma: Large Indian API and finished-formulation manufacturer with significant US/EU DMF presence and penicillin/cephalosporin API capabilities — directly comparable product overlap, but at materially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Syschem compliance and trust

Trust signal

Compliance3 records

Syschem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syschem leadership team

Management profile

Number of profiles

Profiles12 records

Syschem funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syschem M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syschem

What does Syschem do?

Syschem (India) Limited manufactures and sells Active Pharmaceutical Ingredients (APIs) including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. The company also produces specialty chemicals, pharmaceutical intermediates, and a broad range of generic finished dosage forms (tablets, capsules, softgels, injections, syrups, and herbal/personal care products) for domestic and international pharmaceutical buyers, and offers contract manufacturing services.

Is Syschem a public or private company?

Syschem is a public company. It is classified as public and is currently operating.

When was Syschem founded?

Syschem was founded in -1. It employs 51 to 100 people.

Where is Syschem based?

Syschem is headquartered in Chandigarh, India, in the Asia region.

How does Syschem make money?

Four revenue lines are on record. API/Intermediates Manufacturing is the primary driver. The others are generic Formulations, contract Manufacturing and specialty Chemicals.

Who are Syschem's main competitors?

Broad incumbents on record are Lupin, Mankind Pharma, Alkem Laboratories, Cipla and Aurobindo Pharma.

Does Syschem have an API?

No public API is recorded for Syschem.

What industry is Syschem in?

Syschem's product category is Pharmaceutical Manufacturing (APIs and Generic Formulations). Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXSyschem settles Lotus Builders dispute with ₹1.25 crore paymentSyschem (India) Limited settled its dispute with M/s Lotus Builders by paying ₹1.25 crore, the full and final settlement amount. The company will now file applications with the NCLT to withdraw the pending case, following disclosures in 2024 and 2026.ScanXSyschem board notes swap of MD and WTD roles, auditor appointmentSyschem (India) Limited's board noted the members' approval for swapping MD and WTD roles and appointing new statutory auditors. Suninder Veer Singh became MD, Ranjan Jain became WTD, and M/s Bansal Vijay & Associates were appointed as auditors for five years, effective September 30, 2026. The new MD will focus on operational efficiency and cost control.ScanXSyschem India shifts board meeting date to Oct 27, 2026Syschem (India) Limited rescheduled its board meeting from October 26 to October 27, 2026, at 11:00 am at the corporate office. The revision complies with SEBI Listing Obligations and Disclosure Requirements, 2015, and no specific financial results or new corporate actions were disclosed.Business StandardSyschem (India) reports standalone net loss of Rs 1.67 crore in the June 2026 quarterSyschem (India) reported a standalone net loss of Rs 1.67 crore for the quarter ended June 2026, reversing from a net profit of Rs 1.67 crore in the same quarter the previous year. Sales declined marginally by 0.10% to Rs 109.21 crore from Rs 109.32 crore year-on-year. Operating profit margin also contracted significantly to 0.50% from 2.25% in the prior year quarter.ScanXSyschem promoter Ranjan Jain sells 80,270 shares, reduces stakePromoter Ranjan Jain sold 80,270 shares in Syschem (India) Ltd via open market transactions on June 18-19, 2026, reducing his stake to 5.26% of total voting capital. The transaction was disclosed to BSE under Regulation 29(2) of the SEBI (SAST) Regulations, 2011. No reasons for the share sale or future plans for the promoter's remaining holding were disclosed in the filing.ScanXSyschem closes trading window from July 1 till Q1FY27 resultsSyschem (India) Limited has closed its trading window for designated persons and their relatives from July 1, 2026, until 48 hours after the announcement of its Q1FY27 unaudited financial results. The closure is a mandatory compliance measure under SEBI's Prohibition of Insider Trading Regulations, intended to prevent trading on unpublished price-sensitive information. The specific date for the board meeting to approve the results has not yet been announced.Business StandardSyschem (India) standalone net profit rises 278.26% in the March 2026 quarterSyschem (India) reported a 278.26% rise in standalone net profit to Rs 1.74 crore for the quarter ended March 2026, compared to Rs 0.46 crore in the same period last year. Sales for the quarter increased 84.53% to Rs 219.35 crore from Rs 118.87 crore year-on-year. For the full year ended March 2026, net profit surged 2276.09% to Rs 10.93 crore with sales reaching Rs 573.77 crore, up 72.99% from the prior year.Business StandardSyschem (India) standalone net profit rises 734.00% in the December 2025 quarterSyschem (India) reported a 734% rise in standalone net profit to Rs 4.17 crore for the quarter ended December 2025, compared to Rs 0.50 crore in the same quarter of the previous year. Sales also surged 81.97% year-on-year to Rs 141.50 crore from Rs 77.76 crore, driven by improved operational performance with operating profit margin expanding to 4.20% from 1.54%.The Times of IndiaSyschem (India) Share Price Today, Syschem (India) Stock Price Live NSESyschem (India) Ltd., a small-cap company in the pesticides and agro-chemicals sector, reported a significant increase in quarterly income and net profit for the quarter ending December 31, 2025. The company's stock price recently experienced fluctuations but is currently on an upward trend. No major strategic or operational changes are noted in the article.